Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Second Genome.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Second Genome
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
341 Allerton Avenue, South San Francisco, CA 94080
Telephone
Telephone
(650) 440-4606
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Lead development candidate SG-5-00455 shows potential to become first in class PAI-1/2 inhibitor that directly targets mucosal healing in patients with inflammatory bowel disease (IBD).


Lead Product(s): SG-5-00455

Therapeutic Area: Gastroenterology Product Name: SG-5-00455

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 24, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SG-3-06686, enhances effector T cell migration to improve the immune system’s activity against tumors and showed anti-tumor activity in preclinical models as a monotherapy and in combination with anti-Programmed Death Protein-1 (PD-1) treatment.


Lead Product(s): SG-3-06686

Therapeutic Area: Oncology Product Name: SG-3-06686

Highest Development Status: PreclinicalProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 08, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SG-5-00455 delivered directly to the gut via engineered L. lactis system restores barrier function and improves mucosal healing in an ulcerative colitis model.


Lead Product(s): SG-5-00455

Therapeutic Area: Gastroenterology Product Name: SG-5-00455

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 18, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SG-3-0020 enhanced PD-1 expression and IFNg secretion by anti-CD3 activated human T cells in vitro provide a strong rationale for SG-3-0020's potential future use in cancer therapies.


Lead Product(s): SG-3-0020

Therapeutic Area: Oncology Product Name: SG-3-0020

Highest Development Status: PreclinicalProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 07, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines.


Lead Product(s): Undisclosed

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Undisclosed

Partner/Sponsor/Collaborator: Gilead Sciences

Deal Size: $1,538.0 million Upfront Cash: $38.0 million

Deal Type: Collaboration April 06, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY